- Home
- OCTO vs ALLR Comparison
OCTO vs ALLR Comparison
Compare OCTO & ALLR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OCTO
- ALLR
- Stock Information
- Founded
- OCTO 1966
- ALLR 2004
- Country
- OCTO United States
- ALLR United States
- Employees
- OCTO N/A
- ALLR N/A
- Industry
- OCTO
- ALLR Biotechnology: Pharmaceutical Preparations
- Sector
- OCTO
- ALLR Health Care
- Exchange
- OCTO Nasdaq
- ALLR Nasdaq
- Market Cap
- OCTO 4.2M
- ALLR 4.0M
- IPO Year
- OCTO N/A
- ALLR N/A
- Fundamental
- Price
- OCTO $1.36
- ALLR $0.88
- Analyst Decision
- OCTO
- ALLR
- Analyst Count
- OCTO 0
- ALLR 0
- Target Price
- OCTO N/A
- ALLR N/A
- AVG Volume (30 Days)
- OCTO 46.3K
- ALLR 660.5K
- Earning Date
- OCTO 05-16-2025
- ALLR 05-09-2025
- Dividend Yield
- OCTO N/A
- ALLR N/A
- EPS Growth
- OCTO N/A
- ALLR N/A
- EPS
- OCTO N/A
- ALLR N/A
- Revenue
- OCTO $41,576,562.00
- ALLR N/A
- Revenue This Year
- OCTO N/A
- ALLR N/A
- Revenue Next Year
- OCTO N/A
- ALLR N/A
- P/E Ratio
- OCTO N/A
- ALLR N/A
- Revenue Growth
- OCTO N/A
- ALLR N/A
- 52 Week Low
- OCTO $0.98
- ALLR $0.61
- 52 Week High
- OCTO $4.86
- ALLR $20.44
- Technical
- Relative Strength Index (RSI)
- OCTO 49.46
- ALLR 40.96
- Support Level
- OCTO $1.21
- ALLR $0.83
- Resistance Level
- OCTO $1.40
- ALLR $1.06
- Average True Range (ATR)
- OCTO 0.11
- ALLR 0.07
- MACD
- OCTO -0.01
- ALLR -0.02
- Stochastic Oscillator
- OCTO 25.97
- ALLR 24.48
About OCTO Eightco Holdings Inc.
Eightco Holdings Inc operates in Forever 8 Inventory Cash Flow Solution. The company is a dynamic technology-focused company committed to driving growth and innovation through strategic acquisitions and management. Forever 8 focuses on purchasing inventory for e-commerce retailers and is part of its Inventory Solution Business.
About ALLR Allarity Therapeutics Inc.
Allarity Therapeutics Inc is a clinical-stage, precision medicine company. The company is actively advancing a pipeline of in-licensed oncology therapeutics for patients with difficult-to-treat cancers. Its Drug Response Predictor (DRP) technology refines patient selection and improves clinical outcomes. Its pipeline product includes Dovitinib, Stenoparib, Ixempra, and other formulations.